TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3920695

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI, 150 mg/day for 28 days)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AT, dosage not specified for 28 days)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (not specified)
Number of subjects: 33
Study: 3069519

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine (10-40 mg/day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Paracetamol (1000-4000 mg/day)/codeine (60-240 mg/day)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Number of subjects: 107

Group type: COMPARATOR
Intervention: Paracetamol/codeine
Number of subjects: 107
Study: 30476217

Group type: EXPERIMENTAL
Intervention: Regular diet mixed with a commercial synbiotic product at 1.0 g/kg (1.0X)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Regular diet mixed with a commercial synbiotic product at 0.5 g/kg (0.5X)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Regular diet (control)
Number of subjects: 360
Study: 28789467

Group type: EXPERIMENTAL
Intervention: Cathodal ES (CG)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cathodal+anodal ES (CAG)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo ES (PG)
Number of subjects: 63
Study: 26337266

Group type: EXPERIMENTAL
Intervention: Ivermectin (IVM)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Pyrantel (PYR)
Number of subjects: 224
Study: 23437909

Group type: EXPERIMENTAL
Intervention: Standard dose SST (250 μg bolus + continuous infusion of 250 μg/h)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Medium dose SST (500 μg bolus + continuous infusion of 250 μg/h)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High dose SST (250 μg bolus + continuous infusion of 500 μg/h)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control (placebo saline injection + placebo infusion)
Number of subjects: 41
Study: 21300674

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 209
Study: 19894302

Group type: EXPERIMENTAL
Intervention: Cereton 1000 mg intramuscular for 15 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 16550887

Group type: EXPERIMENTAL
Intervention: Project adventure (intervention group)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (traditional physical education)
Number of subjects: 122
Study: 15290411

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) with cuff deflated
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway (LMA) with cuff inflated
Number of subjects: 86

Group type: COMPARATOR
Intervention: Tracheal tube (TT)
Number of subjects: 86
Study: 11199186

Group type: EXPERIMENTAL
Intervention: Cyclical etidronate therapy
Number of subjects: 152

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study: 9050731

Group type: EXPERIMENTAL
Intervention: Operative laparoscopy with 13CO2 laser vaporization and/or resection
Number of subjects: 176

Group type: COMPARATOR
Intervention: Operative laparoscopy with simple monopolar electrocoagulation
Number of subjects: 176

Group type: COMPARATOR
Intervention: Diagnostic laparoscopy without treatment
Number of subjects: 176

Group type: COMPARATOR
Intervention: Danazol 800 mg/day for 3 months after diagnostic laparoscopy
Number of subjects: 176
Study: 8140183

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400 IU)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 250
Study: 3943883

Group type: EXPERIMENTAL
Intervention: Alpha-methyldopa (500 mg oral dose)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 5
Study: 30441841

Group type: EXPERIMENTAL
Intervention: Evening meal (1700 h)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Morning meal (0900 h)
Number of subjects: 19
Study: 27470026

Group type: EXPERIMENTAL
Intervention: Atazanavir 200 mg and ritonavir 100 mg (low dose)
Number of subjects: 559

Group type: COMPARATOR
Intervention: Atazanavir 300 mg and ritonavir 100 mg (standard dose)
Number of subjects: 559
Study: 24643378

Group type: EXPERIMENTAL
Intervention: TVT-S
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: TVT-O
Number of subjects: 122
Study: 22115409

Group type: EXPERIMENTAL
Intervention: Plasmakinetic
Number of subjects: 101

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 101
Study: 19903683

Group type: EXPERIMENTAL
Intervention: CPAP (7 cm H2O for 30 min) after acute altitude exposure (CM)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: CPAP (7 cm H2O for 30 min) after prolonged altitude exposure (MEBC)
Number of subjects: 2
Study: 18953082

Group type: EXPERIMENTAL
Intervention: lisinopril/hydrochlorothiazide with ibuprofen
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: lisinopril/hydrochlorothiazide with piroxicam
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: lisinopril/hydrochlorothiazide with acetaminophen
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: lisinopril/hydrochlorothiazide with ibuprofen or piroxicam (second exposition)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: amlodipine with ibuprofen or piroxicam
Number of subjects: 88

Group type: COMPARATOR
Intervention: control group
Number of subjects: 88
Study: 15987289

Group type: EXPERIMENTAL
Intervention: 200 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 100 mg/week
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 400 mg/week
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 12859036

Group type: EXPERIMENTAL
Intervention: Douching product
Number of subjects: 1827

Group type: EXPERIMENTAL
Intervention: Douching product (frequent use)
Number of subjects: 1827

Group type: COMPARATOR
Intervention: Soft cloth towelette
Number of subjects: 1827
Study: 10855121

Group type: EXPERIMENTAL
Intervention: Metallic esophageal stents
Number of subjects: 63
Study: 8522380

Group type: EXPERIMENTAL
Intervention: 500 mg ceftazidime i.v. t.d.s.
Number of subjects: 127

Group type: COMPARATOR
Intervention: 1,000 mg ceftazidime i.v. t.d.s.
Number of subjects: 127
Study: 2042997

Group type: EXPERIMENTAL
Intervention: HMM II method
Number of subjects: 45

Group type: COMPARATOR
Intervention: Bergqvist method
Number of subjects: 45
Study: 6111438

Group type: EXPERIMENTAL
Intervention: Combination of beta-receptor blocker and diuretic (10 mg pindolol and 5 mg clopamide daily)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Combination of beta-receptor blocker, diuretic and sodium-preserving diuretic (10 mg timolol, 25 mg hydrochlorothiazide and 2.5 mg amiloride)
Number of subjects: 15
Study: 28939629

Group type: EXPERIMENTAL
Intervention: Prolongation of adalimumab dosing interval to once every 3 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Continuation of adalimumab dosing interval every other week
Number of subjects: 55

Group type: COMPARATOR
Intervention: Prolongation group vs continuation group
Number of subjects: 55
Study: 26201083

Group type: EXPERIMENTAL
Intervention: Family-based treatment
Number of subjects: 121

Group type: COMPARATOR
Intervention: Adolescent-focused therapy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Maternal hostility
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Paternal criticism
Number of subjects: 121
Study: 25728105

Group type: EXPERIMENTAL
Intervention: Propolis chewing gum
Number of subjects: 30

Group type: COMPARATOR
Intervention: Xylitol chewing gum
Number of subjects: 30
Study: 22546131

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine (LB) 66, 199, or 266 mg
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine 266 mg
Number of subjects: 100

Group type: COMPARATOR
Intervention: bupivacaine HCl 75 mg
Number of subjects: 100
Study: 20133204

Group type: EXPERIMENTAL
Intervention: Pulsed high-dose dexamethasone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard oral prednisolone
Number of subjects: 40
Study: 17397425

Group type: EXPERIMENTAL
Intervention: Multifactorial falls intervention (two in-home visits, recommendations, referrals, 11 monthly calls, balance exercise plan)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Multifactorial falls intervention
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Multifactorial falls intervention (for subjects with MMSE score of 27 or less)
Number of subjects: 349

Group type: EXPERIMENTAL
Intervention: Multifactorial falls intervention (for subjects with MMSE score of 27 or less and living with someone)
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group (home safety assessment)
Number of subjects: 349
Study: 15736248

Group type: EXPERIMENTAL
Intervention: Trapidil 200 mg t.i.d. for 6 months
Number of subjects: 933

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 933
Study: 11896096

Group type: EXPERIMENTAL
Intervention: Fluorouracil (5-FU) chemotherapy at doses of 370 to 450 mg/m² for 5 consecutive days
Number of subjects: 1093

Group type: COMPARATOR
Intervention: Fluorouracil (5-FU) chemotherapy
Number of subjects: 1093
Study: 9579771

Group type: EXPERIMENTAL
Intervention: Irbesartan 75 mg
Number of subjects: 200

Group type: COMPARATOR
Intervention: Enalapril 10 mg
Number of subjects: 200
Study: 7659440

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (KET) 60 mg before induction (PRE group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (CONT group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Normal saline followed by intravenous ketorolac (KET) 60 mg (POST group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac (KET) 60 mg (PRE group)
Number of subjects: 60
Study: 2683424

Group type: EXPERIMENTAL
Intervention: HDL-rich Cohn-IV-1 fractions infusion (100 ml every 2 weeks)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Cholestyramine and a choleretic drug (permanent medication)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (normolipaemic smokers)
Number of subjects: 14
Study: 30367877

Group type: COMPARATOR
Intervention: 25-gauge FNA (EchoTip Ultra)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: 20-gauge FNB (ProCore)
Number of subjects: 608
Study: 25398072

Group type: EXPERIMENTAL
Intervention: Smoking-specific experiential avoidance
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Trait worry
Number of subjects: 465
Study: 25046539

Group type: EXPERIMENTAL
Intervention: Isoproterenol (ISO: 0.05 μg/kg per minute)
Number of subjects: 9

Group type: COMPARATOR
Intervention: 0.9% saline (control)
Number of subjects: 9
Study: 21834938

Group type: EXPERIMENTAL
Intervention: PP 1420 (2, 4, and 8 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 20507969

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT) - 4 weeks, 30 breaths twice daily at approximately 50% of maximum inspiratory pressure (MIP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham treatment - 4 weeks, 60 breaths once daily at approximately 15% of MIP
Number of subjects: 16
Study: 18699898

Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg.kg(‐1) administered at 4 min before rocuronium
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline administered at 4 min before rocuronium (Control)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg.kg(‐1) administered at 30 s before rocuronium (Late)
Number of subjects: 75
Study: 16192841

Group type: EXPERIMENTAL
Intervention: Amantadine 200 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 12787453

Group type: EXPERIMENTAL
Intervention: Flat plane interocclusal appliance (maxillary splint)
Number of subjects: 20
Study: 9129896

Group type: EXPERIMENTAL
Intervention: Digoxin 1.25 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline intravenously)
Number of subjects: 40
Study: 1901187

Group type: EXPERIMENTAL
Intervention: 50 micrograms vaccine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 100 micrograms vaccine
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 150 micrograms vaccine
Number of subjects: 25
Study: 7092002

Group type: EXPERIMENTAL
Intervention: Tetracycline, 500 mg by mouth every 6 hours for 1 week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo by mouth every 6 hours for 1 week
Number of subjects: 40
Study: 31633625

Group type: EXPERIMENTAL
Intervention: Two-finger (TF) method
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Two-thumb (TT) method
Number of subjects: 42
Study: 30798020

Group type: EXPERIMENTAL
Intervention: Ambulatory assessment methods for treatment adherence and substance use data collection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eligibility criteria verification, treatment adherence monitoring, and remote assessment of substance use and biomarkers
Number of subjects: 0
Study: 27835613

Group type: EXPERIMENTAL
Intervention: Tenofovir-containing regimen (tenofovir + lamivudine/emtricitabine + efavirenz)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Tenofovir-sparing regimen (zidovudine + lamivudine/emtricitabine + efavirenz)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Tenofovir-sparing regimen
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Tenofovir-containing regimen
Number of subjects: 59
Study: 26704144

Group type: EXPERIMENTAL
Intervention: Soft contact lenses with positive spherical aberration (+SA)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control (spherical design) soft contact lenses
Number of subjects: 127
Study: 24560581

Group type: EXPERIMENTAL
Intervention: Alcohol (breath alcohol concentration of .6 g/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 50
Study: 22038192

Group type: EXPERIMENTAL
Intervention: Phonophoresis with corticosteroid (PCS)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Phonophoresis with non-steroid anti-inflammatory drug (PNSAI)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Wrist splinting alone
Number of subjects: 47
Study: 19106767

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) 1-4 mg doses
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 17049767

Group type: EXPERIMENTAL
Intervention: Breast cancer group
Number of subjects: 2492

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2492
Study: 15147428

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 124

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 124
Study: 11642473

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 19
Study: 9541371

Group type: EXPERIMENTAL
Intervention: Oral feedback
Number of subjects: 68

Group type: COMPARATOR
Intervention: Written feedback
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Oral feedback (University 1)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Written feedback (University 1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Oral feedback (University 2)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Written feedback (University 2)
Number of subjects: 68
Study: 7759715

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 2301864

Group type: EXPERIMENTAL
Intervention: Ceravital
Number of subjects: 112

Group type: COMPARATOR
Intervention: Plastipore
Number of subjects: 112
Study: 371887

Group type: EXPERIMENTAL
Intervention: Transfer factor (9 units total, 1 unit = 5 x 10(8) lymphocytes)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 30708350

Group type: EXPERIMENTAL
Intervention: Verum tDCS (20 min; 1 mA; anode [C3], cathode [Fp2])
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study: 29098244

Group type: EXPERIMENTAL
Intervention: 2% sevoflurane for 2 h
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group (0 h exposure)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2% sevoflurane for 0.5 h
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: 2% sevoflurane for 1 h
Number of subjects: 4
Study: 25935771

Group type: EXPERIMENTAL
Intervention: Fructose tolerance test in chronic kidney disease patients
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Fructose tolerance test in metabolic syndrome patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fructose tolerance test in healthy controls
Number of subjects: 75
Study: 24630598

Group type: EXPERIMENTAL
Intervention: Preoperative assessment of pain intensity with active flexion and extension
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Preoperative simple knee range-of-motion test
Number of subjects: 215
Study: 22617128

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (ZOL) 4 mg every 3 weeks for 1 year
Number of subjects: 119

Group type: COMPARATOR
Intervention: No zoledronic acid (control)
Number of subjects: 119
Study: 20059492

Group type: EXPERIMENTAL
Intervention: Capsaicin applied to one side of nasolabial folds
Number of subjects: 144

Group type: COMPARATOR
Intervention: Vehicle applied as control to the other side of nasolabial folds
Number of subjects: 144
Study: 17805038

Group type: EXPERIMENTAL
Intervention: Erwinia asparaginase (ASP) substituted at the same dose and schedule due to allergic reaction to E. coli ASP
Number of subjects: 540

Group type: COMPARATOR
Intervention: Intramuscular E. coli ASP (6000 U/m2x6) followed by intensive weekly intramuscular E. coli ASP (25,000 U/m2/wkx24)
Number of subjects: 540
Study: 12949013

Group type: EXPERIMENTAL
Intervention: Underfed (UF) group
Number of subjects: 19

Group type: COMPARATOR
Intervention: Overfed (OF) group
Number of subjects: 19
Study: 11833245

Group type: EXPERIMENTAL
Intervention: PCPAP 15 minutes, four times per day for three days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: PCPAP 30 minutes, four times per day for three days
Number of subjects: 57

Group type: COMPARATOR
Intervention: Traditional physiotherapy only (control group)
Number of subjects: 57
Study: 9735610

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Systemic-behavioral family therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Nondirective supportive therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 107
Study: 10621922

Group type: EXPERIMENTAL
Intervention: Aluminium-free alginate
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Aluminium-free alginate and Placebo
Number of subjects: 90
Study: 2199148

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (nasal CPAP) for 12 hours after 18 hours of PEEP on the ventilator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no nasal CPAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 343403

Group type: EXPERIMENTAL
Intervention: Prednisolone and isoniazide for six and 12 months
Number of subjects: 280

Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 280
Study: 30580203

Group type: EXPERIMENTAL
Intervention: Manual-only treatment program for caffeine cessation and reduction over a period of 6 weeks; no counseling or additional support.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immediate treatment group (manual-only treatment).
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delayed treatment group (treatment delayed by 7 weeks).
Number of subjects: 0
Study: 27920249

Group type: EXPERIMENTAL
Intervention: 5S (Sort, Set, Shine, Standardize, Sustain) approach as a CQI method implemented at outpatient departments over 12 months
Number of subjects: 3292

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 3292
Study: 26115748

Group type: EXPERIMENTAL
Intervention: Intravenous adenosine triphosphate (ATP) administered after successful PVI to reveal dormant conduction (DC) sites.
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Group A (RC sites differed from DC sites)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Group B (RC sites identical to DC sites)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Group C (RC sites involved both DC and other sites)
Number of subjects: 91
Study: 23809197

Group type: EXPERIMENTAL
Intervention: Cognitive training intervention (Brain Fitness)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Health education active control intervention
Number of subjects: 34
Study: 21997315

Group type: EXPERIMENTAL
Intervention: Rimonabant (10-week treatment)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (10-week treatment)
Number of subjects: 76
Study: 18647427

Group type: EXPERIMENTAL
Intervention: Weight Watchers
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Rosemary Conley
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Atkins
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 300
Study: 16959685

Group type: EXPERIMENTAL
Intervention: Combined systemic and local Pycnogenol treatment
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Local Pycnogenol only
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral Pycnogenol only
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medications only (control group)
Number of subjects: 30
Study: 14976608

Group type: EXPERIMENTAL
Intervention: Fosmidomycin-clindamycin (30 and 5 mg/kg body weight every 12 h for 5 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Fosmidomycin alone (30 mg/kg body weight every 12 h for 5 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Clindamycin alone (5 mg/kg body weight every 12 h for 5 days)
Number of subjects: 36
Study: 11693335

Group type: EXPERIMENTAL
Intervention: 9 MU alpha-interferon three times a week for 6 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6 MU alpha-interferon three times a week for 6 months
Number of subjects: 30
Study: 9469525

Group type: COMPARATOR
Intervention: Morphine (10 mg subcutaneous before surgery and 30 ml saline infiltrated into the wound at skin incision)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Saline (1 ml into an arm before surgery) and Morphine (10 mg in 30 ml saline into the wound at skin incision)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: High doses of i.v. morphine
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (saline)
Number of subjects: 29